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Murine HERS Cells
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Abstract

Objective: The aim of this study was to investigate the effect of near-infrared (NIR) photobiomodulation on the
proliferation and glutathione levels in murine Hertwig’s epithelial root sheath (HERS) cells after poisoning with
vinblastine. Background: Photobiomodulation has been shown to improve wound healing in a number of animal
models. There have been no studies on the effect of photobiomodulation on cancer-related chemotherapy injury
to the cells that initiate tooth root growth. Materials and Methods: Control groups consisted of murine HERS
cells without vinblastine (VB) and cells with vinblastine at 10, 20, and 30 ng/mL (VB10, VB20, and VB30).
Experimental groups consisted of these same groups with light therapy (VB-L, VB10L, VB20L, and VB30L). The
cells were exposed to vinblastine for 1 h. Photobiomodulation consisted of a 75-cm2 gallium-aluminum-arsenide
light-emitting diode (LED) array at an energy density of 12.8 J/cm2, delivered with 50 mW/cm2 power over
256 s. Results: Vinblastine alone significantly decreased HERS cell proliferation and glutathione levels at all
concentrations (VB10 [55%, p < 1.0108]; VB20 [72%, p < 1.0109]; VB30 [80%, p < 1.01010]; and VB10
[36%, p < 0.0001]; VB20 [49%, p < 1.0106]; VB30 [53%, p < 1.0107] respectively). Photobiomodulation
significantly increased cell proliferation at all levels of vinblastine exposure (VB10L [þ50%, p < 0.0001]; VB20L
[þ45%, p < 0.05]; VB30 [þ39%, p < 0.05]) but not of the control (þ22%, p ¼ 0.063). The photobiomodulation
significantly increased glutathione production in all concentrations of vinblastine except 20 ng/mL (VB10L
[þ39%, p ¼ 0.007]; VB20L [þ19%, p ¼ 0.087]; VB30 [þ14%, p ¼ 0.025]) and the control (þ12%, p ¼ 0.13).
Conclusions: Photobiomodulation demonstrated an improvement in proliferation and glutathione levels in
vinblastine-poisoned murine HERS cells.

Introduction

T

he long-term effects of anti-neoplastic therapy
have gained importance as survival rates from childhood
cancers have increased in the past decades. The chemotherapeutic agents used in the treatment of childhood cancers are
toxic to proliferating cancer cells through varying mechanisms of action, and all potentially result in injury to nontarget tissues also proliferating at the time of treatment. Acute
oral effects include oral mucositis, while long-term effects
include decreased salivary gland function and a wide range of
dental developmental anomalies, including enamel hypoplasia, microdontia, taurodontia, root blunting and thinning,
and hypodontia.1–3 The frequency and severity of dental developmental anomalies depend on the developmental stage of
the tooth at the time of treatment, as well as the dose and
repetition of the chemotherapeutic agent.1 Numerous studies

of the long-term effects of chemotherapy on dental development have found that the most common abnormality is
atypical root morphology.2–7
Hertwig’s epithelial root sheath (HERS) cells are considered
to be the cells responsible for root formation. The apical migration of these cells during root development determines the
eventual morphology of the root.8,9 HERS cells proliferating at
the time of chemotherapy are damaged by the non-selective
nature of the drugs, resulting in altered root morphology.10
The long-term clinical implications of the short, thin, tapered
roots of permanent teeth often seen in childhood cancer survivors include limitations on future orthodontic treatment,
prosthetic abutment consideration, and periodontal health.
There is currently no treatment or prevention for these morphologic alterations.
Vinblastine is a vinka alkyloid chemotherapeutic agent
commonly used in the treatment of childhood cancers, which
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shows a strong correlation with disturbances in root development.1 Vinblastine’s primary mechanism of action is the
inhibition of microtubule formation, preventing cell proliferation. In addition, vinblastine has been shown to decrease
the production of glutathione, an antioxidant that protects
cells from free radicals and participates in protein synthesis,
resulting in decreased cell viability.11,12
Photobiomodulation is a novel, non-invasive treatment
that has been shown to help certain cells and tissues recover
from injury.13,14 The treatment entails irradiating cells or
tissues with a specific energy density of light at certain
wavelengths in the far-red to near-infrared (NIR) spectrum
(630–1000 nm) using low-energy lasers or light-emitting diodes
(LEDs).
The purpose of this study was to determine the in vitro
effects of photobiomodulation on an immortalized line of
murine HERS cells poisoned by the chemotherapeutic agent
vinblastine. Vinblastine was chosen as the test chemotherapeutic agent due to its known cause of root morphology
alterations, its relative safety when handled, and its direct
action on cells without prior metabolic alteration into an
active form. We hypothesize that photobiomodulation applied to HERS cells subjected to chemical injury by vinblastine will improve proliferation and function of these cells.
Demonstrating this effect may suggest a possible preventive
therapy to the developmental root anomalies often seen in
the survivors of childhood cancer.
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Vinblastine exposure
Twenty-four hours after plating, cultures were exposed to
vinblastine diluted in sterile phosphate buffered saline (PBS)
for 1 h at concentrations of 0, 10, 20, or 30 ng/mL added to
the culture medium based on group assignments. LD50 of
vinblastine was determined by pilot dose response assays.
NIR-LED light treatment
One hour after vinblastine exposure, light treatment
groups were exposed to 670 nm wavelength light generated
by gallium-aluminum-arsenide LEDs (Quantum Devices,
Inc., Barneveld, WI), at an energy density of 12.8 J/cm2, delivered with 50 mW/cm2 power over 256 s, as determined by
pilot dose response assays. Control cultures received no light
treatment. Cells were incubated for 24 h at 338C, 5% CO2.
Cell proliferation quantification, and glutathione assay
Forty-eight hours after plating (24 h after vinblastine
and photobiomodulation), cell counts were performed under
a microscope using a hemocytometer, and glutathione
production was measured fluorometrically, as relative fluorescence units (RFU), with a Bio-Tek FLx800 Fluorometer
(Bio-Tek Instruments, Inc., Winooski, VT) using the Promega
GSH-Glo Glutathione Assay (Promega Corporation, Madison, WI).
Statistical analysis

Materials and Methods
HERS Cultures
Immortalized murine HERS cells (obtained from Dr.
Zeichner-David, University of Southern California) were
cultured according to the protocol described by ZeichnerDavid.8 Cells were cultured in a 75-cm2 tissue culture flask
(BD Falcon, Bedford, MA) with Dulbecco’s Modified Eagle’s
Medium, supplemented with 1% penicillin/streptomycin,
1% l-glutamine and 10% heat-inactivated fetal bovine serum,
and incubated at 338C, 5% CO2. Cells in log phase growth
were harvested and cultured in 24-well tissue culture plates
and black-walled 96-well tissue culture plates (Corning, Inc.,
Corning, NY) at a cell density of 62,500 cells/cm2, as determined by pilot seeding density assays. Cells were then incubated overnight at 338C, 5% CO2.
Group assignments
Plated HERS cell cultures were divided into eight
groups based on dose of vinblastine (Abraxis Pharmaceutical Products, Schaumburg, IL) and exposure to light
treatment. Control groups consisted of HERS cells without
vinblastine (VB) and cells treated with 10, 20, and 30 ng/mL
(VB10, VB20, VB30) of vinblastine. Treatment groups
consisted of the same groups as the controls, but with
photobiomodulation (VB-L, VB10L, VB20L, and VB30L).
The test concentrations of vinblastine were based upon an
estimated clinical dose. A vinblastine concentration of approximately 7.5 ng/mL was determined by calculating the
estimated cellular concentration of this chemical based on a
20-kg child and a dose of 6 mg/m2. Experiments were conducted on four generations of cells, in triplicates for each
group.

All values for cell proliferation (cell counts) and glutathione levels were calculated using Microsoft Office Excel and
expressed as mean  standard deviation (SD). Comparisons between vinblastine levels and light groups were analyzed using Student’s t test (SPSS Statistics, IBM Co.,
Chicago, IL). A p value of 0.05 was considered statistically
significant.
Results
Group comparisons demonstrated that vinblastine exposure negatively affected HERS cell proliferation (VB10
[55%] p < 1.0108; VB20 [72%] p < 1.0109; VB30
[80%] p < 1.01010) and glutathione production (VB10
[36%] p < 0.0001; VB20 [49%] p < 1.0106; VB30 [53%]
p < 1.0107) at all doses of vinblastine. Within the no light
treatment groups, 10 ng/mL vinblastine exposure resulted in
a 55% decrease in cell proliferation and a 36% decrease in
glutathione production compared to the control group. At
20 and 30 ng/mL vinblastine, cell proliferation and glutathione production were significantly decreased from the
control and 10 ng/mL vinblastine groups ( p < 0.05), but
were not significantly different from each other. This demonstrated a distinct dose–response relationship of vinblastine
on HERS cell proliferation and glutathione production, with
an approximate median lethal dose (LD50) of 10 ng/mL
vinblastine.
Photobiomodulation significantly reduced vinblastine’s
negative effect on HERS cell proliferation ( p < 0.05; Table 1)
and glutathione production ( p < 0.05; Table 2). When compared to the same dose of vinblastine without light treatment, the light treatment significantly increased cell
proliferation at all levels of vinblastine exposure (VB10L
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Table 1. Cell Proliferation Results

Vinblastine
dose (ng/mL)
Control/0
10
20
30

No light
treatment [av.
cells/mL,
10,000 (SD)]
41.6
18.6
11.6
8.5

(8.2)
(3.4)
(4.6)
(3.6)

% Change

p Value*

–
55%
72%
80%

8.91E-09
2.07E-10
1.19E-11

Light treatment
[av. cells/mL,
10,000 (SD)]
50.8
27.9
16.8
11.8

(14)
(5.6)
(6.8)
(3.7)

% Change

p Value**

þ22%
þ50%
þ45%
þ39%

0.063
5.68E-05
0.041
0.034

Average cell counts (SD). t-test results p values: *compared to control, no light treatment; **compared to same dose vinblastine, no light
treatment. Bold values indicate statistical significance.

[þ50%] p < 0.0001; VB20L [þ45%] p < 0.05; VB30 [þ39%]
p < 0.05) and showed a 22% increase in control cells receiving
no vinblastine, but not reaching statistical significance
( p ¼ 0.063). Light treatment significantly increased glutathione production at 10 and 30 ng/mL vinblastine (VB10L
[þ39%] p ¼ 0.007; VB30 [þ14%] p ¼ 0.025; Table 2). Light
treatment resulted in a 12% increase in glutathione production in control cells receiving no vinblastine (VB  L;
P ¼ 0.13), and a 19% increase at 20 ng/mL vinblastine
(VB20L, p ¼ 0.087), which were not statistically significant.
At the LD50 of 10 ng/mL vinblastine, light treatment resulted in a 50% increase in cell proliferation and a 39% increase in glutathione production, thus restoring cell
proliferation to 68% and glutathione production to 89% of
control cells receiving no vinblastine and no light treatment.
Discussion
The results demonstrate that vinblastine has a negative
effect on HERS cell proliferation and glutathione production
that is in agreement with a previous study on vinblastine’s
effects in these types of cells.10 In addition, the results
demonstrate that photobiomodulation significantly reduced
these negative effects.
A consistent dose–response curve for the effects of vinblastine on in vitro cultures of murine HERS cells was
established, with an approximate LD50 of 10 ng/mL vinblastine. This value is close to the estimated pharmacologic
dose of vinblastine of 7.5 ng/mL given in cancer treatment,
calculated from the mg/m2 dose. This indicates that HERS
cells are sensitive to vinblastine at/near commonly used
pharmacologic doses, and adds support to clinical findings
that abnormal root morphology in childhood cancer survivors is the result of damage to HERS cells proliferating at the
time of chemotherapy.1–7

There was a beneficial effect of photobiomodulation on
HERS cell recovery from vinblastine exposure. The greatest
effects of the light treatment were noted at the LD50. Beyond
this level, improvements in cell proliferation and glutathione
production were likely diminished due to the extent of initial
injury sustained, which surpassed the benefits derived from
the light treatment. At the LD50, light treatment restored cell
proliferation and glutathione production to within 68% and
89% respectively of control cells receiving no light treatment.
It is unknown if this would have any beneficial outcomes on
an in vivo level.
The non-statistically significant increase in glutathione
production in the 20 ng/mL vinblastine group, when there
were statistically significant increases in the 10 and 30 ng/mL
groups, may be due to a slightly larger standard deviation
measurement in this group compared to the other groups,
affecting the statistics. It may also be due to naturally occurring differences in many types of mammalian cells,
including epithelial cells. These differences can cause individual cells within a seemingly similar group to differ widely
in their response to uniform physiological stimuli, such as
oxidative stress and other environmental insults. These naturally occurring differences that cause cell-to-cell variability
may develop through normal mechanisms and can include
genetic differences, changes in protein expression, fluctuations in biochemical reactions, differences in cell cycle phases, and natural variation in levels of important reactants.15,16
This heterogeneous cellular response may play a role in the
phenomenon of ‘‘fractional killing’’ of tumor cells after chemotherapy.16
It is not believed that heating the cell cultures contributed
to the results obtained. Temperature probes were not utilized
in this study due to previously published evidence that light
therapy does not produce significant tissue heating.17 In
addition, during experiments of photodynamic therapy in a

Table 2. Glutathione Assay Results
Vinblastine
dose (ng/mL)
Control/ 0
10
20
30

No light
treatment
[Av. RFU (SD)]
43087
27600
21773
20358

(8819)
(6347)
(3873)
(3053)

% Change

p Value*

–
36%
49%
53%

6.14E-05
1.19E-07
2.42E-08

Light
treatment
[Av. RFU (SD)]
48147
38389
25988
23107

(6833)
(10910)
(7160)
(5421)

% Change

p Value**

þ12%
þ39%
þ19%
þ14%

0.13
0.007
0.087
0.025

Average RFU (SD). t-test results p values: *compared to control, no light treatment; **compared to same dose vinblastine, no light
treatment. Bold values indicate statistical significance. RFU: relative fluorescence unit.
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canine model, 670-nm light at an energy density of 100 J/cm2
administered directly into the brain parenchyma did not
cause the temperature of brain tissue to rise by more than
18C.18
NIR light appears to exert therapeutic effects in multiple
ways. Primarily, the light appears to alter the activity of
cytochrome c oxidase in mitochondria13,14,19,20 improving
energy metabolism and production, thus increasing energy
available for cell and tissue repair. NIR light also increases
the production of growth factors responsible for wound
healing13 and causes the production of low level amounts of
reactive oxygen species, resulting in up-regulation of genes
involved in wound healing.21 In vitro studies of photobiomodulation show increased mitochondrial oxidative metabolism;14,19,22 increased cell growth in murine fibroblasts,
rat osteoblasts, rat skeletal muscle cells, and human epithelial
cells;23 recovery of rat neurons from toxin inactivation;20,22
accelerated wound healing;13,23,24 and protection against
methanol-induced retinal toxicity.25
How photobiomodulation can assist in overcoming the
cytotoxic effects of vinblastine are still unknown, but there is
some evidence indicating that mitochondrial activity may be
an important factor. Drug resistance by cancer cells to chemotherapeutic agents is associated with an increased expression of P-glycoprotein (Pgp) on the cell wall.26 Pgp has
an integral ATP binding site and may require increased
levels of ATP. Jia et al.27 demonstrated that the ATP required
for this Pgp efflux pump is primarily supplied by the mitochondrial F1F0ATPase pathway. Photobiomodulation has
been shown to increase the amount of ATP produced in the
mitochondria13,14,19,20 and also assists in upregulating genes
necessary for cellular healing.20 Although there is no published literature to suggest it, if photobiomodulation is able
to induce the cells to produce more Pgp, this, along with
increased ATP production, might be able to prevent apoptosis of vinblastine-treated HERS cells in a manner similar
to Pgp-associated vinblastine-resistance in tumor cells. More
research is required to test this theory.
Conclusion and Summary
This study is a first step in determining the possible benefits of photobiomodulation to HERS cells in this population
of cancer patients. This preliminary work demonstrated a
beneficial effect of photobiomodulation on in vitro cultures
of murine HERS cells injured by the chemotherapeutic agent
vinblastine. Much further research is needed to address the
in vivo effects, but photobiomodulation is the first treatment
to demonstrate a beneficial effect on HERS cells after vinblastine exposure.
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